ClinicalTrials.gg
CompletedNCT00168701Updated Aug 28, 2023

Efficacy and Safety of BG00012 in MS

A Phase 2 interventional study of BG00012 in Multiple Sclerosis, sponsored by Biogen. Completed at 42 sites in 10 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-08-28.

Sponsored by Biogen · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Oct 2004, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis — 1 open to participants now, 1 under way, 1 of them phase 3. Dimethyl Fumarate · Multiple Sclerosis.

Enrollment
5th of 22
260 · median 86
Started
2004
the only one that year
Phase 2
3 of 22
none open now
Registered
1st of 22
by date
Lead sponsor
17 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, this one is the 5th largest by enrollment, is the only one that started in 2004, is one of 3 in phase 2, and was the 1st registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

1 of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis is open now. Recruiting first, the newest first:

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, or all of them as a file.
02

Study summary

Determine the efficacy, safety, and tolerability of BG00012 in MS patients.

Read the detailed description

The study will be divided into two parts: Part 1 will be a 24-week, blinded, placebo-controlled treatment phase followed by Part 2, a 24-week blinded, safety extension phase in which all subjects will receive BG00012.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • MRI
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be 18 to 55 years old, inclusive, at the time of .
  2. Must have a confirmed diagnosis of relapsing-remitting MS according to McDonald criteria #1-4 (McDonald et al, 2001; Appendix 2).
  3. Must have a baseline EDSS between 0.0 and 5.0, inclusive.
  4. Must have experienced at least one relapse within the 12 months prior to randomization, with a prior cranial MRI demonstrating lesion(s) consistent with MS OR show evidence of Gd-enhancing lesions of the brain on an MRI performed within the 6 weeks.
  5. Male and female subjects must be willing to take appropriate measures to prevent pregnancy.

Exclusion criteria

Exclusion Criteria:

  1. Primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold, 1996 [Appendix 3]).
  2. History of .
  3. History of severe allergic or anaphylactic reactions or known drug .
  4. History of abnormal laboratory results indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic (other than MS), and/or other major disease.
  5. History of (HIV).
  6. History of drug or alcohol abuse (as defined by the Investigator) within the 2 years prior to randomization.
  7. An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to randomization.
  8. Body weight >100 kg.
  9. Positive for antibody and/or positive for surface antigen (HBsAg) at screening.
  10. Any of the following abnormal blood tests at screening.
  11. Any previous treatment with FUMADERM®, FAG-201, or BG00012.
  12. A medication history that precludes entry into the study.
  13. Female subjects who are currently pregnant or breast-feeding.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
260 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. The primary endpoint for the primary objective is the total number of MRI lesions at Weeks 12, 16, 20, and 24.

    Time frame: Weeks 12, 16, 20, and 24

Secondary outcomes

  1. The secondary endpoints will include measuring the changes in MRIs from baseline until Week 24, changes in other MS measurements q12 weeks, and the annualized relapse rate and proportion of changes at Weeks 24 and 48.

    Time frame: Weeks 24 and 48

07

Study locations

42 sites
  • Faculty Hospital St. Anne
    Bmo, 656 91, Czechia
  • Faculty Hospital
    Hradec Kralove, 500 05, Czechia
  • Hospital of Pardubice
    Pardupice, 532 03, Czechia
  • Faculty Hospital of Plzen
    Plzen, 304 60, Czechia
  • General Teaching Hospital
    Prague, 128 02, Czechia
  • Bochum am St. Josef-Hospital
    Bochum, 44791, Germany
  • Heinrich-Heine-Universitat
    Dusseldorf, 40225, Germany
  • George-August-Universitat Goettigen
    Goettigen, 37073, Germany
  • Uzsoki Hospital
    Budapest, 1145, Hungary
  • University of Debrecen
    Debrecen, 4012, Hungary
  • Petz Aladar County Hospital
    Gyor, 9024, Hungary
  • VUMC
    Amsterdam, 1081 HV, Netherlands
  • Academic Hospital Rotterdam
    Rotterdam, 3015 GD, Netherlands
  • SamodzielnyPubliczny Szpital Kliniczny
    Bialystok, 15-276, Poland
  • Niesalezny Zespol Opieki Zdrowognej
    Bialystok, 15-420, Poland
  • 10 Wojskowy Szpital Kliniczny z Poliklinika
    Bydgoszcz, 85-681, Poland
  • Wojewodzki Szpital Specjalistczny
    Gdansk, 80-803, Poland
  • Slaskiej Akademii Medycznej
    Katowice-Ligota, 41-741, Poland
  • Szpital Uniwersytecki w Krakowie
    Krakow, 31-503, Poland
  • Panstwowy Szpital Kliniczny
    Lodz, 90-153, Poland
  • Samodzielny Publiczny Centralny Szpital
    Warszawa, 01-097, Poland
  • Moscow, 1153682, Russian Federation
  • Moscow, 123182, Russian Federation
  • Moscow, 123367, Russian Federation
  • Moscow, 127018, Russian Federation
  • Novgorod, 603076, Russian Federation
  • Novosibirsk, 630075, Russian Federation
  • St. Petersburg, 194044, Russian Federation
  • St. Petersburg, 194291, Russian Federation
  • St. Petersburg, 197022, Russian Federation
  • St. Petersburg, 197376, Russian Federation
  • MS Centrum
    Molndal, 431 80, Sweden
  • Karolinska University Hospital
    Stockholm, 141 86, Sweden
  • Karolinska University Hospital
    Stockholm, 171 76, Sweden
  • Kantonsspital Basel
    Basel, CH 4.31, Switzerland
  • Hacettepe Unisersitesi
    Ankara, 6100, Turkey
  • Istanbul University
    Istanbul, 34303, Turkey
  • University of Instanbul
    Istanbul, TR-34390, Turkey
  • Multiple Sclerosis Reseach Clinic
    London, SE1 9RT, United Kingdom
  • Institute of Neurology
    London, WC1N 3BG, United Kingdom
  • Royal Hampshire Hospital
    Sheffield, S10 2JF, United Kingdom
  • University Hospital of North Staffordshire
    Stoke-on-Trent, ST4 7LN, United Kingdom
08

References and documents

Publications

  • Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L, Liu S, Matta A, Phillips JT, Robertson D, von Hehn CA, Campbell J, Spach K, Yang L, Fox RJ. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. Neurology. 2019 Apr 9;92(15):e1724-e1738. doi: 10.1212/WNL.0000000000007262. Epub 2019 Mar 27. PubMed 30918100 ↗
  • Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, O'Gorman J, Novas M, Dawson KT, Phillips JT. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin. 2014 Feb;30(2):251-62. doi: 10.1185/03007995.2013.849236. Epub 2013 Oct 22. PubMed 24131282 ↗
  • Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008 Oct 25;372(9648):1463-72. doi: 10.1016/S0140-6736(08)61619-0. Erratum In: Lancet. 2009 Apr 18;373(9672):1340. PubMed 18970976 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2004 to primary completion in Mar 2006, 17 months.

Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 17 months is below that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
StartActual
Oct 1, 2004
Primary completionActual
Mar 31, 2006
CompletionActual
Mar 31, 2006
Last update
Aug 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00168701
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Oct 1, 2004
Primary completion
Mar 31, 2006
Completion
Mar 31, 2006
Last update
Aug 28, 2023

Study contacts

Ludwig Kappos, Prof
principal investigator · Kantonsspital Basel
Gilmore O'Neill, MB,MRCPI,MMedSc
study director · Biogen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion